TerminatedPhase 2NCT04866836

A Study of Tislelizumab Combined With Radiotherapy as the Second-line Treatment of Advanced Biliary Malignant Tumors

Studying Cholangiocarcinoma

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
The First Affiliated Hospital with Nanjing Medical University
Principal Investigator
Changxian Li, PhD
The First Affiliated Hospital with Nanjing Medical University
Intervention
Radiotherapy(combination_product)
Enrollment
20 target
Eligibility
18-75 years · All sexes
Timeline
2020 – 2022

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04866836 on ClinicalTrials.gov

Other trials for Cholangiocarcinoma

Additional recruiting or active studies for the same condition.

See all trials for Cholangiocarcinoma →

← Back to all trials